# Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

> **NCT01437605** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 14 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** MAGE-A3 ASCI injections without Poly IC:LC
- **DRUG:** MAGE-A3 ASCI injections with Poly IC:LC

## Key facts

- **NCT ID:** NCT01437605
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-11
- **Primary completion:** 2018-07-18
- **Final completion:** 2018-07-18
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Treatment Ineffective
- **Last updated:** 2019-12-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437605, "Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01437605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*